Get started
Author

Simon Thomas

Observed names: S Thomas, S. Thomas, Thomas, S, Thomas, S., Thomas, Simon
ORCID: 0000-0003-3410-5698
Observed ORCIDs: 0000-0003-3410-5698, 0000-0001-7119-9545
OpenAlex ID: A5057490890
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
2014 · Brian Philip, Evangelia Kokalaki, et al. · Blood · 410
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
2021 · Shaun Cordoba, Shimobi Onuoha, et al. · Nature Medicine · 302
PDF
Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma
2020 · Karin Straathof, Barry Flutter, et al. · Science Translational Medicine · 205
PDF
An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma
2017 · Lydia Lee, Benjamin Draper, et al. · Blood · 182
PDF
A Rapamycin-Activated Caspase 9-Based Suicide Gene
2018 · Maria Stavrou, Brian Philip, et al. · Molecular Therapy · 101
PDF
Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells
2008 · D P Hart, S-A Xue, et al. · Gene Therapy · 73
An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers
2016 · Simon Thomas, Karin Straathof, et al. · PLoS ONE · 66
PDF
Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice
2009 · S.-A. Xue, L. Gao, et al. · Haematologica · 62
PDF
TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial
2024 · Kate Cwynarski, Gloria Iacoboni, et al. · Nature Medicine · 52
Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
2019 · Rakesh Popat, Sonja Zweegman, et al. · Blood · 50
Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy
2023 · Lydia Lee, Wen Chean Lim, et al. · Journal for ImmunoTherapy of Cancer · 48
PDF
Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR
2023 · Evangelia Kokalaki, Biao Ma, et al. · Molecular Therapy · 44
PDF
Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.
2020 · Wendy Osborne, Maria Marzolini, et al. · Journal of Clinical Oncology · 43
Tunable control of CAR T cell activity through tetracycline mediated disruption of protein–protein interaction
2021 · Alastair Hotblack, Evangelia K. Kokalaki, et al. · Scientific Reports · 29
PDF
Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies
2024 · Mathieu Ferrari, Matteo Righi, et al. · Nature Communications · 26
PDF
Abstract CT145: A Cancer Research UK phase I trial of anti-GD2 chimeric antigen receptor (CAR) transduced T-cells (1RG-CART) in patients with relapsed or refractory neuroblastoma
2018 · Karin Straathof, Barry Flutter, et al. · Cancer Research · 26
Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study
2019 · Kirit M. Ardeshna, Maria A V Marzolini, et al. · Blood · 21
Novel Fas-TNFR chimeras that prevent Fas ligand-mediated kill and signal synergistically to enhance CAR T cell efficacy
2023 · Callum McKenzie, Mohamed El-Kholy, et al. · Molecular Therapy — Nucleic Acids · 16
Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors
2023 · Matteo Righi, Isaac Gannon, et al. · Cancer Immunology Research · 15
PDF
Study of AUTO3, the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22, Followed By Anti-PD1 Consolidation in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Alexander Study
2018 · Kirit Ardeshna, Maria A V Marzolini, et al. · Blood · 11
Structure Guided Engineering of Highly Specific Chimeric Antigen Receptors for the Treatment of T Cell Lymphomas
2018 · Shimobi Onuoha, Mathieu Ferrari, et al. · Blood · 10
Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2
2023 · Julia Taylor, Anna Bulek, et al. · Frontiers in Immunology · 9
PDF
CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT
2014 · Karl S Peggs, Eleni Tholouli, et al. · Blood · 9
Designer Small-Molecule Control System Based on Minocycline-Induced Disruption of Protein–Protein Interaction
2024 · Ram Jha, Alexander Kinna, et al. · ACS Chemical Biology · 8
Abstract 2183: Targeting TRBC1 and 2 for the treatment of T cell lymphomas
2020 · Mathieu Ferrari, Vania Baldan, et al. · Cancer Research · 6
Works count: 67
Citation count: 1,857
H-index: 17
I10-index: 21
Year
Topic
Type